



Transforming the treatment of Asia prevalent cancers



- Focus on Asia-prevalent tumours**
eg Gastric, biliary tract, liver
- Proprietary pipeline of 5 drugs**
Lead in pivotal studies
- Strong cash position**
USD 66M raised in the last year and over USD 10M revenues
- Partnerships with world-leading pharma and biotechs**
Including BMS, CSL, Ammirall
- Led by clinical development veterans**
With global pharma experience

Varlitinib (ASLAN001) is a novel agent that has shown strong efficacy in a variety of difficult-to-treat tumour types. Varlitinib has completed phase 2 studies in gastric and breast cancer, and is entering pivotal studies for BTC. *Varlitinib* has received Orphan Drug Designation from US FDA for cholangiocarcinoma and gastric cancer.

ASLAN002 is a highly potent cMET and RON inhibitor, an immune checkpoint inhibitor. In August 2016, BMS acquired the global rights to ASLAN002.

ASLAN003 is a novel DHODH inhibitor, which has shown to be a potent inducer of p53 and is entering phase 2.

ASLAN004 is a monoclonal IL4/IL13 antibody targeting asthma and certain tumour types.

ASLAN005 is a monoclonal antibody targeted against RON, an immune checkpoint inhibitor.

Modybodies are a novel type of antibody fragments which can be linked together into heterodimers/trimers to inhibit multiple targets.

Program	Target	Indication	Disc	PC	Ph 1	Ph 2	Pivotal	Originator
Varlitinib/ ASLAN001	panHER Growth pathway inhibitor	BTC	██████████	██████████	██████████	██████████	██████████	ARRAY
		Gastric cancer	██████████	██████████	██████████	██████████		
		Breast cancer	██████████	██████████	██████████	██████████		
		Colorectal cancer	██████████	██████████	██████████	██████████		
ASLAN002	MET/RON Immune checkpoint inhibitor	Solid tumours	██████████	██████████	██████████	BMS acquired global rights in 2016	Bristol-Myers Squibb	
ASLAN003	DHODH Metabolic stress inducer via p53	Solid tumours	██████████	██████████	██████████		Almirall	
ASLAN004	IL4/13 Macrophage anti-tumour enhancer	Asthma, Solid tumours	██████████	██████████	██████████		CSL	
ASLAN005	RON Immune checkpoint inhibitor	Solid tumours	██████████	██████████	██████████		Agency for Science, Technology and Research	
Modybodies	mAb fragments Targets not disclosed	Oncology	██████████	██████████	██████████		NANYANG TECHNOLOGICAL UNIVERSITY	

Proprietary Portfolio*

PARTNERS

Partnerships with leading global pharma and international biotech companies:



INVESTORS

We have raised over 3 billion NTD to date. We are supported by leading healthcare investors and the Singapore government:



UNDERWRITER AND AUDITOR



SERVICE PARTNERS





DEVELOPING IN ASIA FOR GLOBAL MARKETS

- Focus on Asia prevalent tumour types
- We run studies across Asia, where patient numbers are high
- Data is leveraged for approvals in US, EU and other global markets where often these are orphan diseases and accelerated approval is possible
- Few – if any – approved therapies for these indications such as gastric cancer, colorectal cancer and biliary tract cancer.



EXPERIENCED MANAGEMENT

Dr Carl Firth CEO	<ul style="list-style-type: none"> • Formerly Head of Asia Healthcare Investment Banking, Merrill Lynch • 16 years in pharmaceutical industry, including roles in Asia and China leading new product development
Dr Bertil Lindmark CMO	<ul style="list-style-type: none"> • Former CSO, Global Head of R&D and Exec Director at Almirall, leading team of 550 across 3 sites, responsible for 4 major market approvals in US / EU • Previously served as Head of Clin Dev, AstraZeneca
Dr Mark McHale COO	<ul style="list-style-type: none"> • Former Head of Molecular Sciences at AstraZeneca Respiratory & Inflammation • Over 25 years pharmaceutical R&D experience
Jeff Tomlinson CBO	<ul style="list-style-type: none"> • 12 years senior BD and IP experience at North American biotech companies and VC • 5 years pharmaceuticals R&D
Ben Goodger General Counsel	<ul style="list-style-type: none"> • Previously Head of IP Licensing and Transactions at Osborne Clarke • 20 years of experience in IP and licensing
Charlie Hsu IR Director	<ul style="list-style-type: none"> • 10 years venture capital experience across Asia-Pac • Over 10 years in Taiwan high tech listed companies, including roles in IR and commercial
Sir David Lane Chair of Scientific Advisory Board	<ul style="list-style-type: none"> • Discoverer of p53 in 1979 • Chief Scientist, A*Star, Director of Ludwig Institute • Previously Chief Scientist, Cancer Research UK

CONTACT

SINGAPORE

83 Clemenceau Avenue
#12-03 UE Square
Singapore 239920
+65 6222 4235

TAIWAN

32F International Trade Building
333 Keelung Road Sec 1
Taipei 11012
+886 2757 6700

CHINA

1206 Chong Hing Finance Center
288 Nanjing Road West, Huangpu District
Shanghai 200003
+86 21 6133 7950

AUSTRALIA

58 Gipps Street,
Collingwood
Victoria, 3066

www.aslanpharma.com

contact-taiwan@aslanpharma.com

OUR AWARDS

- Asian Biotech of the Year 2016 (Biopharm Asia)
- Executive of the Year (BioPharm Asia finalist)
- Best Company in Emerging Market (Scrip finalist)
- Most Promising Company of the Year (ChinaBio)
- Small Business Rising Star (British Chamber)
- Young Professional (British Chamber finalist)
- Best Company in Emerging Market (Scrip finalist)
- Best Management Team (Scrip finalist)
- Awarded Red Herring Top 100 (Asia)
- Finalist for Red Herring Top 100 (Global)
- Top 100 Scrip Leader

SCRIP

British Chamber of Commerce

RED HERRING 100 ASIA WINNER

CHINABIO

BioPharma ASIA